BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
1.985
-0.055 (-2.70%)
Jan 8, 2026, 2:00 PM EST - Market open
BioXcel Therapeutics Market Cap
BioXcel Therapeutics has a market cap or net worth of $43.41 million as of January 8, 2026. Its market cap has increased by 177.33% in one year.
Market Cap
43.41M
Enterprise Value
117.72M
1-Year Change
177.33%
Ranking
Category
Stock Price
$1.99
Market Cap Chart
Since March 8, 2018, BioXcel Therapeutics's market cap has decreased from $172.57M to $43.41M, a decrease of -74.84%. That is a compound annual growth rate of -16.14%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jan 7, 2026 | 44.61M | 27.50% |
| Dec 31, 2025 | 34.99M | 88.57% |
| Dec 31, 2024 | 18.56M | -78.51% |
| Dec 29, 2023 | 86.35M | -85.65% |
| Dec 30, 2022 | 601.94M | 5.82% |
| Dec 31, 2021 | 568.84M | -49.47% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Mar 8, 2018 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 992.16B |
| Johnson & Johnson | 499.90B |
| AbbVie | 412.54B |
| UnitedHealth Group | 309.53B |
| AstraZeneca | 297.23B |
| Novartis AG | 273.49B |
| Merck & Co. | 269.55B |
| Novo Nordisk | 254.60B |